from the Euro presentation: p30 "current cash = $188mil
future cash flow: Abbott/J&J (US$55-60mil) to Q1 2011." plus other upfronts/milestones/royalties.
I guess they could afford a dividend, but it's just my opinion they really want to get some of their own antibodies to market for some security. I don't hold for exactly that reason, am watching it very closely. I used to hold in EGX days but sold after the merger. It must be frustrating for PTD holders.
AAH Price at posting:
88.0¢ Sentiment: None Disclosure: Not Held